title: [The association between the therapeutic agent and the compliance of the patients with inflammatory bowel diseases].
abstract: OBJECTIVE
  Adherence of the patients with inflammatory bowel diseases is important to maintain the remission. However, the patients do not always keep their appointments for treatment. The aim of this study was to investigate the clinical factors associated with adherence of patients in terms of appointment keeping.
  
  
  METHODS
  A total of 73 subjects were retrospectively investigated from September 2005 to January 2012 at Dongguk University Ilsan Hospital (Goyang, Korea). We reviewed medical records including the age, sex, residence, medications, the disease activity, and the rate of keeping the date. A punctual visit was defined as outpatient visit on the scheduled date ±7 days. Punctual patients for the visit were defined as their punctual visit rates exceed 90%.
  
  
  RESULTS
  Male to female ratio was 2.4:1. Mean age was 41.5±15.4 years (range, 20 to 78 years). Ulcerative colitis was 53 cases (72.6%) and Crohn's disease was 20 cases (27.4%). Mean duration of disease was 42.0±41.6 months (range, 4 to 226 months). Mean puntual visit rate was 86.7±16.0% (range, 27 to 100). Thirty-eight patients (52.1%) were punctual patients for the visit. Azathioprine/6-mercaptopurine treatment was associated with punctual patients for the visit (odd ratio, 3.19; 95% confidence interval, 1.12 to 9.09; p=0.03). However, other clinical factors did not influence the punctual visit rates.
  
  
  CONCLUSIONS
  Our study demonstrated that the use of azathioprine/6-mercaptopurine was associated with keeping the appointment for meeting the doctor. Further prospective study would be necessary.
authors.affiliation: Department of Internal Medicine, Dongguk University Ilsan Hospital, the Graduate School, Dongguk University, Goyang, Korea.
authors.forename: Yun-Seong
authors.initials: YS
authors.lastname: Kang
authors.forename: So Young
authors.initials: SY
authors.lastname: Kim
authors.forename: Min Ho
authors.initials: MH
authors.lastname: Jo
authors.forename: Hyoun Woo
authors.initials: HW
authors.lastname: Kang
authors.forename: Jun Kyu
authors.initials: JK
authors.lastname: Lee
authors.forename: Yun Jeong
authors.initials: YJ
authors.lastname: Lim
authors.forename: Moon Soo
authors.initials: MS
authors.lastname: Koh
authors.forename: Jin Ho
authors.initials: JH
authors.lastname: Lee
authors.forename: Chang Hun
authors.initials: CH
authors.lastname: Yang
authors.forename: Jae Hak
authors.initials: JH
authors.lastname: Kim
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003710:Demography; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D010349:Patient Compliance; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012737:Sex Factors
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab; D015122:Mercaptopurine; D001379:Azathioprine